放疗联合长期ADT:LHRH拮抗剂与激动剂在高危前列腺癌中的EORTC GUCG-1414 III期随机试验
EORTC GUCG-1414 III期随机试验纳入379例极高危局限性或局部晚期前列腺癌患者,随机接受degarelix(LHRH拮抗剂)或LHRH激动剂联合盆腔放疗及转移灶治疗,主要终点为放疗后6个月内PSA谷值反应。结果显示degarelix未改善PSA谷值反应(52% vs 60%,OR 0.73,95%CI 0.43-1.22;p=0.9),两组2年PFS均为88%,但degarelix在基线心血管疾病患者中CV事件发生率较低。
要点
- degarelix与LHRH激动剂相比未提高放疗后6个月内PSA谷值<0.1 ng/ml的比例。
- 两组2年无进展生存率均为88%,不良事件发生率相似(89% vs 88%)。
- 基线有心血管疾病的患者中,degarelix组CV事件少于激动剂组。
核心结论
- degarelix未改善放疗后6个月内PSA谷值反应,但与LHRH激动剂相比在基线心血管疾病患者中CV事件发生率较低。
研究设计与样本
- EORTC GUCG-1414 III期随机试验,2017-2023年纳入379例具至少两项高危特征且M0(常规影像)或M1a/b(≤3个病灶,先进影像)的前列腺癌患者。
- 随机接受18、24或36个月ADT(degarelix n=190;LHRH激动剂 n=189)联合盆腔EBRT及所有转移灶治疗。
- 因入组缓慢,主要终点由PFS改为放疗后6个月内PSA谷值反应(<0.1 vs ≥0.1 ng/ml)。
主要发现
- PSA谷值<0.1 ng/ml在激动剂组为60%,degarelix组为52%(OR 0.73,95%CI 0.43-1.22;p=0.9)。
- 两组2年PFS均为88%。
- 不良事件发生率激动剂组89%,degarelix组88%。
- 基线有心血管疾病的41例患者中,激动剂组4例、degarelix组1例发生CV事件;激动剂组有2例CV相关死亡。
- degarelix改善下尿路症状,尤其在基线IPSS≥13的患者中。
关键数值与推荐
- 主要终点PSA谷值<0.1 ng/ml比例:激动剂组60% vs degarelix组52%,OR 0.73(95%CI 0.43-1.22),p=0.9。
- 2年PFS两组均为88%。
- 不良事件发生率:激动剂组89%,degarelix组88%。
临床怎么用
- 对于接受放疗联合长期ADT的高危前列腺癌患者,degarelix与LHRH激动剂在PSA谷值反应和2年PFS上无显著差异。
- 基线有心血管疾病的患者可考虑使用degarelix以降低CV事件风险。
- degarelix可能改善下尿路症状,尤其对基线IPSS≥13的患者。
局限性
- 试验提前关闭,把握度不足,无法充分评估PFS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: External beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) is standard for high-risk prostate cancer. EORTC 1414 compared ADT with a luteinizing hormone-releasing hormone (LHRH) antagonist (degarelix) or an LHRH agonist in patients who received EBRT. METHODS: Between 2017 and 2023, 379 patients with prostate cancer with at least two high-risk features (prostate-specific antigen [PSA] ≥20 ng/ml, Gleason score ≥8, cN1, or cT3-4) and stage M0 on conventional imaging or stage M1a/b (n = ≤3 lesions) on advanced imaging were enrolled. Patients were randomized to receive 18, 24, or 36 mo of ADT (degarelix, n = 190; LHRH agonist, n = 189) with pelvic EBRT and treatment of all metastases. Owing to low accrual, the primary endpoint was changed from progression-free survival (PFS) to the PSA nadir response (<0.1 vs ≥0.1 ng/ml) within 6 mo after EBRT. KEY FINDINGS AND LIMITATIONS: Median age was 72 yr. A PSA nadir of <0.1 ng/ml was achieved by 60% of patients in the agonist arm and 52% in the degarelix arm (odds ratio 0.73, 95% confidence interval 0.43-1.22; p = 0.9). Two-year PFS was 88% in both arms. Adverse events occurred in 89% of agonist and 88% of degarelix patients. Among 41 patients with baseline cardiovascular (CV) disease, four in the agonist arm and one in the degarelix group experienced a CV event. Two CV-related deaths occurred in the agonist arm. Degarelix improved lower urinary tract symptoms, particularly in patients with a baseline International Prostate Symptom Score of ≥13. Limitations include early closure and insufficient power to assess PFS. CONCLUSIONS AND CLINICAL IMPLICATIONS: Degarelix did not improve the PSA nadir response within 6 mo after EBRT in comparison to LHRH agonists, but was associated with lower incidence of CV events among patients with pre-existing CV disease.
引用
- Zilli T, Böhmer D, Roeder A, et al. Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial. Eur Urol Oncol. 2025. PMID: 41206286. doi:10.1016/j.euo.2025.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。